Advertisement
Advertisement
DNLI
Denali Therapeutics Inc. Common Stock
20.18
USDSponsored
+0.43
+2.18%
Mar 20, 15:59 UTC -4
Closed
After-Market
20.01
-0.17
-0.86%
DNLI Earnings Reports
Positive Surprise Ratio
DNLI beat 16 of 33 last estimates.
48%
Next Report
Date of Next Report
May 04, 2026
Estimate for Q1 26 (Revenue/ EPS)
$431.15K
/-$0.73
Implied change from Q4 25 (Revenue/ EPS)
--
/--
Implied change from Q1 25 (Revenue/ EPS)
--
/-6.41%
Denali Therapeutics Inc. Common Stock earnings per share and revenue
On Feb 26, 2026, DNLI reported earnings of -0.73 USD per share (EPS) for Q4 25, beating the estimate of -0.75 USD, resulting in a 3.82% surprise. Revenue reached --, compared to an expected 1.18 million, with a -100.00% difference. The market reacted with a -3.90% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 10 analysts forecast an EPS of -0.73 USD, with revenue projected to reach 431.15 thousand USD, implying an increase of 0.00% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Alvotech Ordinary Shares
Report Date
Mar 18, 2026 For Q4 25
Estimate
-$0.04
Actual
-$0.37
Surprise
-706.10%
Eton Pharmaceutcials, Inc. Common Stock
Report Date
Mar 19, 2026 For Q4 25
Estimate
$0.09
Actual
$0.05
Surprise
-45.53%
Cellectis S.A. - ADR
Report Date
Mar 19, 2026 For Q4 25
Estimate
-$0.26
Actual
-$0.26
Surprise
+1.78%
Candel Therapeutics, Inc. Common Stock
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.25
Actual
-$0.54
Surprise
-115.31%
Protalix BioTherapeutics, Inc. Common Stock
Report Date
Mar 18, 2026 For Q4 25
Estimate
$0.00
Actual
-$0.07
Surprise
-1472.55%
Eledon Pharmaceuticals, Inc. Common Stock
Report Date
Mar 19, 2026 For Q4 25
Estimate
-$0.20
Actual
-$0.10
Surprise
+51.78%
Artiva Biotherapeutics, Inc. Common Stock
Report Date
Mar 30, 2026 For Q4 25
Estimate
-$0.84
Actual
-Surprise
-
Milestone Pharmaceuticals Inc. Common Shares
Report Date
Mar 20, 2026 For Q4 25
Estimate
-$0.16
Actual
-$0.16
Surprise
+1.96%
Spruce Biosciences, Inc. Common Stock
Report Date
Apr 13, 2026 For Q4 25
Estimate
-$8.14
Actual
-Surprise
-
Pelthos Therapeutics Inc.
Report Date
Mar 19, 2026 For Q4 25
Estimate
-$4.21
Actual
-$2.83
Surprise
+32.82%
FAQ
What were Denali Therapeutics Inc. Common Stock's earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, Denali Therapeutics Inc. Common Stock reported EPS of -$0.73, beating estimates by 3.82%, and revenue of $0.00, -100% below expectations.
How did the market react to Denali Therapeutics Inc. Common Stock's Q4 2025 earnings?
The stock price moved down -3.9%, changed from $22.29 before the earnings release to $21.42 the day after.
When is Denali Therapeutics Inc. Common Stock expected to report next?
The next earning report is scheduled for May 04, 2026.
What are the forecasts for Denali Therapeutics Inc. Common Stock's next earnings report?
Based on 10
analysts, Denali Therapeutics Inc. Common Stock is expected to report EPS of -$0.73 and revenue of $431.15K for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement